Efficacy of convalescent plasma therapy in improving survival in non-immunized COVID-19 patients

Publication date: Jun 24, 2025

While the study highlights critical determinants such as age and the potential of predictive biomarkers, it also notes the variability in treatment responses across different demographic and clinical groups. Survival analysis evaluating the efficacy of plasma versus standard therapy showed statistically significant advantages favouring patients treated with plasma. Beyond immediate treatment outcomes, the study investigated potential long-term effects and prognostic indicators associated with plasma therapy. Transcriptomic analyses have revealed significant changes in gene expression that could serve as biomarkers for disease progression and treatment response. Our findings align with this, demonstrating significant population heterogeneity across treatment groups and highlighting the need for further investigation into underlying determinants and effect modifiers. In contrast, our unicentric retrospective cohort study compared 100 patients treated with CP to 145 who received standard treatment. Our study identified substantial population heterogeneity among treatment groups, which requires further investigation into underlying determinants and effect modifiers.

Semantics

Original Article